What is BioSyntech, Inc. (BSYI) stock price today?

BioSyntech, Inc. (BSYI) is currently trading at $0.00.

What is BSYI return on equity (ROE)?

BioSyntech, Inc.'s return on equity (ROE) is 185.71%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is BioSyntech, Inc.'s market cap?

BioSyntech, Inc. has a market capitalization of $229033.

OTC · Biotechnology

BioSyntech, Inc. (BSYI) Stock

$0.00 OTC: BSYI Healthcare

BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds.

Valuation

Metric	Value
Price	$0.00
Market Cap	$229033
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	7.88
EPS (TTM)	$-0.13
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	185.71%
ROA	-185.71%
ROCE	234.28%
Gross Margin	60.82%
Operating Margin	—
Net Margin	—
Debt/Equity	-1.71
Current Ratio	0.42

Annual Financials (USD)

Metric	2004	2005	2006	2007	2008
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-5.0M	$-6.0M	$-7.0M	$-9.0M	$-11.0M
Net Profit	$-5.0M	$-7.0M	$-8.0M	$-9.0M	$-13.0M
EPS	$-0.14	$-0.17	$-0.09	$-0.10	$-0.13
Op Margin	-2685.2%	-10349.0%	-2996.2%	-3358.0%	-27056.3%

Balance Sheet (USD)

Metric	2004	2005	2006	2007	2008
Total Assets	$5.0M	$15.0M	$16.0M	$6.0M	$7.0M
Total Liabilities	$7.0M	$6.0M	$5.0M	$4.0M	$14.0M
Cash	$1.0M	$5.0M	$4.0M	$3.0M	$4.0M
Borrowings	$6.0M	$2.0M	$4.0M	$3.0M	$12.0M

Latest News

5 Insightful Analyst Questions From Nasdaq’s Q2 Earnings Call StockStory · Aug 1, 2026 Michigan Supreme Court rejects permit for Enbridge oil pipeline under Great Lakes Associated Press · Aug 1, 2026 Major airline cancels 81 flights as strike looms, no refunds TheStreet · Aug 1, 2026 Genco (GNK) Faces Fresh Valuation Challenge As Diana Escalates Proxy Fight Simply Wall St. · Aug 1, 2026 UMB Financial (UMBF) Earnings And Dividend Hike Put Valuation In Focus Simply Wall St. · Aug 1, 2026

Cash Flow (USD)

Metric	2004	2005	2006	2007	2008
Operating Cash Flow	$-4.0M	$-6.0M	$-8.0M	$-8.0M	$-10.0M
Investing Cash Flow	$1.0M	$-7.0M	$-2.0M	$8.0M	$0
Financing Cash Flow	$0	$-1.0M	$-1.0M	$0	$-1.0M
Net Cash Flow	$-1.0M	$4.0M	$-1.0M	$-1.0M	$1.0M
Free Cash Flow	$-4.0M	$-6.0M	$-8.0M	$-9.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.81
FCF Yield	-3054.11%
Quick Ratio	0.45
Interest Coverage	-43.09
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AOXGAoxing Pharmaceutical Company, Inc.	$0.00	—	-86.98	$266756	0.00%
CHNXFChitogenX Inc.	$0.01	+0.00%	-0.23	$627628	0.00%
DRWNQuantum Medical Transport, Inc.	$0.00	—	0.36	$23978	0.00%
EMDFGarrison Film Productions Inc.	$0.00	—	-0.33	$140450	0.00%
GPFTGrapefruit USA, Inc.	$0.00	—	0.17	$71740	0.00%

About BioSyntech, Inc.

BioSyntech, Inc. is dedicated to developing advanced biotherapeutic thermogels aimed at both repairing tissues and delivering therapeutic compounds. The company's key product pipeline features BST-CarGel, a biodegradable gel designed for cartilage repair; BST-InPod, intended for alleviating heel discomfort; BST-DermOn, for managing and healing chronic wounds; BST-Ossifil, used in bone void filling; BST-Ossifix, which provides structural support for bones; and BST-Disc, focused on restoring intervertebral discs. Beyond these, BioSyntech offers injectable products leveraging BST-Gel technology to precisely deliver biotherapeutics. Its technological assets also include Arthro-BST, an arthroscopic device for the non-destructive evaluation of cartilage degradation or repair, and Mach-1, a micromechanical testing system for assessing the properties of various tissues and materials. The company also manufactures ultra-pure chitosans under the Ultrasan brand and offers both manufacturing and analytical services. Founded in 1994 and based in Laval, Canada, BioSyntech Inc. initiated administration proceedings under the Bankruptcy and Insolvency Act on May 12, 2010, and is currently undergoing reorganization.

BioSyntech, Inc. (BSYI) stock trades at $0.00 with a market capitalization of $229033. The stock is valued at price-to-book of 0.00, price-to-sales of 7.88.

On profitability, BioSyntech, Inc. generates a return on equity (ROE) of 185.71% (not meaningful, as shareholders' equity is negative), return on capital employed of 234.28%.

Official website: biosyntech.com/

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.